Flywheel

The potential for artificial intelligence (AI) and machine learning (ML) to reshape drug discovery and development is immense. From expediting learning and driving discoveries to managing large-scale data sets and generating fresh insights, the true scale of AI’s influence on the industry is only starting to be understood. But with great potential comes great responsibility.…

Minneapolis-based Flywheel has received $54 million in a Series D round backed by NVIDIA, Microsoft, Hewlett Packard Enterprise and other strategic investors. Flywheel will invest the cash to fuel growth in core verticals, the pharmaceutical and public sector healthcare sectors. A notable Big Pharma customer is Genentech. The company also aims to ramp up expansion…

Big data and AI offer massive opportunities to the pharmaceutical industry — in theory. In reality, many companies are struggling to realize the potential of these tools. Some organizations have been hesitant or resistant to leveraging the technologies. Others may have attempted to embrace them early on but are now beginning their second or third…

Ask a pharma researcher how well they’re able to leverage their organization’s medical imaging data, and you might hear a discouraging response. While most pharma companies have massive amounts of clinical and medical imaging data, often, most of the imaging data isn’t ready for modern research processes and infrastructure. This imaging data is an untapped…

The research data platform Flywheel has announced that Roche (OTCMKTS:RHHBY) and its subsidiary Genentech are using its cloud-scale informatics platform to ingest, standardize and analyze medical imaging data to streamline drug discovery. Minneapolis-based Flywheel says the process provides a swifter and more efficient means to curate data at the terabyte and petabyte scales. Specifically, Roche and…